Published in Nat Commun on June 29, 2016
RNA interference targeting Aurora-A sensitizes glioblastoma cells to temozolomide chemotherapy. Oncol Lett (2016) 0.76
MicroRNA-376b promotes breast cancer metastasis by targeting Hoxd10 directly. Exp Ther Med (2016) 0.75
Phosphodiesterase-5 inhibition suppresses colonic inflammation-induced tumorigenesis via blocking the recruitment of MDSC. Am J Cancer Res (2017) 0.75
MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK. Oncol Lett (2017) 0.75
Antitumor effect of Batf2 through IL-12 p40 up-regulation in tumor-associated macrophages. Proc Natl Acad Sci U S A (2017) 0.75
Motor neuron degeneration following glycine-mediated excitotoxicity induces spastic paralysis after spinal cord ischemia/reperfusion injury in rabbit. Am J Transl Res (2017) 0.75
Autophagy plays a protective role in motor neuron degeneration following spinal cord ischemia/reperfusion-induced spastic paralysis. Am J Transl Res (2017) 0.75
miR-365 induces hepatocellular carcinoma cell apoptosis through targeting Bcl-2. Exp Ther Med (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Cancer statistics, 2013. CA Cancer J Clin (2013) 84.72
The Pfam protein families database. Nucleic Acids Res (2009) 37.98
Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med (2007) 20.19
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Angiogenesis as a therapeutic target. Nature (2005) 11.89
Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov (2007) 11.46
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov (2004) 9.96
Batf3 deficiency reveals a critical role for CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science (2008) 7.87
An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progression. Nat Protoc (2007) 3.81
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol (2011) 3.58
The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells. Nat Immunol (2011) 3.21
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71
The possible significance of the ferrous oxidase activity of ceruloplasmin in normal human serum. J Biol Chem (1966) 2.58
Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res (2002) 1.73
Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol (2008) 1.57
Specificity through cooperation: BATF-IRF interactions control immune-regulatory networks. Nat Rev Immunol (2013) 1.50
Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell (2010) 1.47
B-ATF: a novel human bZIP protein that associates with members of the AP-1 transcription factor family. Oncogene (1995) 1.43
Copper-dependent activation of hypoxia-inducible factor (HIF)-1: implications for ceruloplasmin regulation. Blood (2005) 1.42
Repression of IL-2 promoter activity by the novel basic leucine zipper p21SNFT protein. J Immunol (2000) 1.39
Role of hypoxia-inducible factor-1 in transcriptional activation of ceruloplasmin by iron deficiency. J Biol Chem (2000) 1.35
Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN). Proc Natl Acad Sci U S A (2008) 1.22
Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer. Lancet Oncol (2010) 1.06
High tumor angiogenesis is associated with poorer survival in carcinoma of the cervix treated with radiotherapy. Clin Cancer Res (1998) 1.03
Extended resections of liver metastases from colorectal cancer. World J Surg (2007) 1.00
Decreased expression of BATF2 is associated with a poor prognosis in hepatocellular carcinoma. Int J Cancer (2011) 0.99
The influence of dendritic cell infiltration and vascular endothelial growth factor expression on the prognosis of non-small cell lung cancer. Clin Cancer Res (2002) 0.98
Decreased expression of BATF2 is significantly associated with poor prognosis in oral tongue squamous cell carcinoma. Oncol Rep (2013) 0.93
Inhibition of AP-1 by SARI negatively regulates transformation progression mediated by CCN1. Oncogene (2010) 0.90
BATF2 Deficiency Promotes Progression in Human Colorectal Cancer via Activation of HGF/MET Signaling: A Potential Rationale for Combining MET Inhibitors with IFNs. Clin Cancer Res (2015) 0.89
Novel mechanism of MDA-7/IL-24 cancer-specific apoptosis through SARI induction. Cancer Res (2013) 0.89
The function of SARI in modulating epithelial-mesenchymal transition and lung adenocarcinoma metastasis. PLoS One (2012) 0.88
Regulation of metastasis in colorectal adenocarcinoma: a collision between development and tumor biology. Surgery (2008) 0.87
Soluble vascular endothelial growth factor decoy receptor FP3 exerts potent antiangiogenic effects. Mol Ther (2012) 0.85
Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression. Cancer Cell (2014) 0.84
Progastrin a new pro-angiogenic factor in colorectal cancer. Oncogene (2014) 0.82
Temporal and pharmacological characterization of angiostatin release and generation by human platelets: implications for endothelial cell migration. PLoS One (2013) 0.81
Ceruloplasmin alters intracellular iron regulated proteins and pathways: ferritin, transferrin receptor, glutamate and hypoxia-inducible factor-1α. Exp Eye Res (2012) 0.81
Plasmid-based STAT3-siRNA efficiently inhibits breast tumor growth and metastasis in mice. Neoplasma (2011) 0.81
Adjuvant bevacizumab in colon cancer: where did we go wrong? Lancet Oncol (2012) 0.80
Preemptive surgery. Surgery (2006) 0.77